Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05346757

Validation of a microRNA-based Fecal (miRFec) Test for Colorectal Cancer Screening, Surveillance and Diagnosis

The present study aims to compare effectiveness and cost-effectiveness of the miRFec test with respect to fecal immunochemical test (FIT) for the detection of advanced colorectal neoplasm among individuals participating in colorectal cancer (CRC) screening, surveillance and diagnosis.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospital Clinic of Barcelona

Barcelona, 08036, Spain

Location status: Recruiting

Location contact

Mireia Diaz

CONTACT

[email protected]

+34932275703

About this study

The miRFec test -a Gradient Boosting Machine-generated algorithm that includes two fecal miRNAs (miR-421 and miR-27a-3p) and fecal hemoglobin concentration, along with age and gender- is more effective and cost-effective than FIT for the identification of patients with advanced colorectal neoplasm (i.e. colorectal cancer, advanced adenomas or advanced serrated lesions) among individuals participating in colorectal cancer screening and surveillance programs, and diagnosis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female aged 50 to 75 (average-risk) referred to colonoscopy-based CRC screening.
  • Male or female aged 30 to 80 with family history of CRC (moderate-risk) referred to colonoscopy-based CRC screening.
  • Male and female aged 18 or older with personal history of colorectal polyps referred to colonoscopy surveillance.
  • Male and female aged 18 or older with personal history of CRC referred to colonoscopy surveillance.
  • Male and female aged 18 or older with colorectal symptoms referred to diagnostic colonoscopy.

Exclusion criteria

  • Lack of informed consent to participate
  • Personal history of Lynch syndrome
  • Personal history of adenomatous or hamartomatous polyposis
  • Personal history of serrated polyposis syndrome
  • Personal history of inflammatory bowel disease
  • Personal history of total colectomy for any reason
  • Family history of Lynch syndrome
  • Family history of adenomatous or hamartomatous polyposis
  • Family history of serrated polyposis syndrome

Treatment and study plan

miRFec test

Diagnostic Test

The miRFec test actually corresponds to the combination of fecal hemoglobin concentration (ie. FIT) and fecal miRNA expression

Primary outcomes

  1. Sensitivity for advanced colorectal neoplasm

    Time frame: Through study completion, an average of 3 years

    To compare the sensitivity of the miRFec test with respect to FIT for the detection of advanced colorectal neoplasm

Secondary outcomes

  1. Specificity

    Time frame: Through study completion, an average of 3 years

    To compare the specificity of the miRFec test with respect to FIT

  2. Sensitivity for colorectal cancer

    Time frame: Through study completion, an average of 3 years

    To compare the sensitivity of the miRFec test with respect to FIT for the detection of colorectal cancer

  3. Sensitivity for advanced adenomas

    Time frame: Through study completion, an average of 3 years

    To compare the sensitivity of the miRFec test with respect to FIT for the detection of advanced adenomas

  4. Sensitivity for advanced serrated lesions

    Time frame: Through study completion, an average of 3 years

    To compare the sensitivity of the miRFec test with respect to FIT for the detection of advanced serrated lesions

  5. Detection rate for advanced colorectal neoplasm

    Time frame: Through study completion, an average of 3 years

    To compare the detection rate for advanced colorectal neoplasm of the miRFec test with respect to FIT

  6. Discrimination capacity for advanced colorectal neoplasms

    Time frame: Through study completion, an average of 3 years

    To compare the discrimination capacity of the miRFec score and fecal hemoglobin concentration for the detection of advanced colorectal neoplasm

  7. Discrimination capacity for colorectal cancer

    Time frame: Through study completion, an average of 3 years

    To compare the discrimination capacity of the miRFec score and fecal hemoglobin concentration for the detection of colorectal cancer

  8. Cost-effectiveness for advanced colorectal neoplasm detection

    Time frame: Through study completion, an average of 3 years

    To compare the cost (euros) for detecting one advanced colorectal neoplasm using the miRFec test with respect to the corresponding figure using FIT

Study contacts

Contact information is provided by the study sponsor or research team.

Mireia Diaz

CONTACT

[email protected]

932275703

Sponsors and collaborators

Lead sponsor

Fundacion Clinic per a la Recerca Biomédica

Other

Registry information

Official study title

Prospective, Multicenter, Comparative, Paired Study to Validate a microRNA-based Fecal Test for Colorectal Cancer Screening. The miRFec Study

Acronym: miRFec

Important dates

Study start
2022
Primary completion
2027
Study completion
2027
First posted
Apr 26, 2022
Registry last updated
Mar 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.